PDCD1 and interstitial lung disease: Considering the history of interstitial lung disease in our patient, we chose to target PD-L1 to leave intact the interaction between PD1 and its alternative ligand, PD-L2, which had the theoretical benefit of promoting self-tolerance in the lungs, where the PD1/PDL-2 pathway plays a role in regulating inflammation (8).